Altimmune Inc
$3.58
(as of Jun 27, 2:08 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Altimmune Inc
Stock Price
$3.58
Ticker Symbol
ALT
Exchange
NASDAQ
Industry Information for Altimmune Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Fundamentals for Altimmune Inc
Market Capitalization
$625,334,976
EBITDA
$-98,033,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.26
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
81,107,000
Percent Owned by Insiders
0.76%
Percent Owned by Institutions
47.87%
52-Week High
52-Week Low
Technical Indicators for Altimmune Inc
Analyst Ratings for Altimmune Inc
Strong Buy
5
Buy
3
Hold
1
Sell
0
Strong Sell
0
News About Altimmune Inc
Jun 26, 2025, 2:01 PM EST
Thursday’s market has seen significant movements across various stocks, with some experiencing notable gains while others face declines. See more.
Jun 26, 2025, 1:14 PM EST
ATLANTA, June 26, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Altimmune, Inc. See more.
Jun 26, 2025, 7:57 AM EST
[Red arrow And dollar finance decline graph- Stock image]
See more.
Jun 26, 2025, 7:08 AM EST
Investing.com -- Altimmune, Inc. See more.